Several tau antibodies have been evaluated in preclinical models of AD, and these antibodies have targeted linear epitopes in the tau N-terminus [25–29], central domain [30], MTBRs [31, 32] or specific phosphorylation sites such as pThr231 [33], pSer396 [33, 34], pSer396/pSer404 [35, 36], pSer404 [37], pSer413 [34], or pSer422 [38]. This evidence concerns the gene MAPT and Alzheimer disease.